INTRODUCTION
The efficacy of peritoneal dialysis (PD) as a treatment modality largely depends on the peritoneal membrane integrity. Dysfunction of the peritoneum as a dialysis organ may result from progressive membrane injury occurring over time on PD. The underlying pathophysiological mechanisms involve a gradual rise in small solute transport due to an increase in peritoneal perfusion and a decrease in peritoneal hydraulic conductance due to tissue fibrosis. 1 Both these processes are related to peritoneal angiogenesis. On the one hand, an increase in peritoneal vascularity increases the surface area available for solute diffusion and leads to rapid dissipation of the osmotic gradient that drives ultrafiltration. On the other hand, angiogenesis is a prominent feature of tissue repair, scar formation and fibrosis. Indeed, it has been estimated that up to 75% of patients with ultrafiltration failure may have increased vascular surface area. 2;3 Moreover, peritoneal biopsies taken from PD patients show that fibrosis occurs significantly more often in the presence of vasculopathy, 4 and the density of peritoneal blood vessels and sub-mesothelial and perivascular fibrosis are significantly greater in patients with membrane failure. [4] [5] [6] Animal models of PD confirm the existence of an inverse correlation between increased vascularization and ultrafiltration. 7 These studies suggest that a decline in ultrafiltration could be partially abrogated by antiangiogenic therapy. 7 Vascular endothelial growth factor (VEGF) is the most important pro-angiogenic mediator. 8 The impact of VEGF on peritoneal vascularity is demonstrated by the association of genetic polymorphisms determining increased VEGF production with increased peritoneal solute transport. 9 Moreover, the rates of VEGF appearance in the dialysate are elevated in patients with high peritoneal transport status. 10;11 Several mechanisms are implicated in peritoneal VEGF induction in PD. 12 One of the factors involved has been suspected to be interleukin-6 (IL-6), since IL-6 concentrations in the drained dialysate correlate with peritoneal solute transport rates [13] [14] [15] and dialysate levels of VEGF. 10;14 Interestingly, it has been demonstrated that the peritoneal mesothelium is the main source of both VEGF 16;17 and IL-6. 18;19 Although VEGF can be induced by several inflammatory cytokines 20 , IL-6 has not been classically viewed as a driver of VEGF production in mesothelial cells, as these do not express the cognate IL-6 receptor (IL-6R). 21 On the other hand, however, they do express gp130, a signal transduction element for IL-6, which allows them to respond to IL-6 in the presence of soluble IL-6R (sIL-6R). Indeed, this process of socalled IL-6 trans-signaling plays critical role in controlling chemokine production and contributes to successful resolution of inflammation. 21 The mechanism appears to be particularly active in the acute phase of peritonitis when mesothelial cells release large quantities of IL-6 19 and infiltrating leukocytes shed sufficient levels of sIL-6R. 21 Interestingly, viral IL-6 (vIL-6) that binds directly to gp130 in a process resembling IL-6 trans-signaling, is also capable of inducing VEGF in mesothelial cells. 22 We have therefore hypothesized that IL-6 together with sIL-6R might be important in controlling VEGF production in human peritoneal mesothelial cells (HPMC). Here, we characterized the transcriptional regulation of VEGF in HPMC and identified transcription factors STAT3 and SP4 as forming a novel axis linking IL-6 and VEGF production in the peritoneum.
RESULTS

Induction of VEGF by IL-6 and sIL-6R in mesothelial cells
Since mesothelial cells are the main source of peritoneal VEGF, we have examined whether VEGF production by human peritoneal mesothelial cells (HPMC) can be regulated by IL-6either directly through classical IL-6 receptor signaling or IL-6 trans-signaling.
Indeed, neither IL-6 nor sIL-6R alone had significant effect on VEGF protein release.
However, simultaneous exposure to IL-6+sIL-6R resulted in a significant time-and dosedependent increase in VEGF secretion ( Fig. 1A and 1B ). The greatest effect was achieved with both IL-6 and sIL-6R at a dose of 100 ng/ml. This effect was confirmed by specific blocking experiments. Here, antibodies against either IL-6 or sIL-6R, but not with control IgG, inhibited the induction of VEGF by HPMC (Fig. 1C ). The effect exerted by a combination of IL-6 and sIL-6R on VEGF secretion was accompanied by a corresponding increase in VEGF mRNA ( Fig. 1D ). These observations prompted us to examine in more detail the signaling events leading to VEGF gene induction.
Activation of VEGF gene promoter by IL-6 and sIL-6R
To investigate how the IL-6+sIL-6R complex impacts on the activity of the VEGF gene promoter, HPMC were transiently transfected with VEGF luciferase reporter gene constructs and stimulated with IL-6 and sIL-6R. This resulted in a time-dependent increase in VEGF promoter activity, which peaked at 6 hours ( Fig. 2A ). Exposure for 6 hours to IL-6 or sIL-6R alone had no stimulatory effect on the full length VEGF promoter. In contrast, the combination of IL-6 and sIL-6R strongly increased the activity of the VEGF promoter ( Fig. 2B ).
To identify VEGF promoter regions mediating the response to IL-6 trans-signaling, functional '-deletions of the VEGF promoter were generated. Truncation of the promoter region spanning positions -268 to -53 resulted in a loss of VEGF promoter activity to respond to stimulation with IL-6+sIL-6R ( Figure 2C ). This result suggested that the region identified comprised essential regulatory elements for the VEGF promoter activity. The in silico analysis predicted that the region contained high affinity binding sites for the transcription factors SP1 and SP4. To determine which of these transcription factors was regulated by IL-6+sIL-6R, electrophoretic mobility shift assays (EMSA) was performed.
Activation of the transcription factor SP4 by IL-6 and sIL6-R
EMSA was performed using biotin-labeled double-stranded oligonucleotides corresponding to positions -59 to -82 (SP4) and -80 to -103 (SP1) of the VEGF promoter.
Analysis of nuclear extracts from cells stimulated with IL-6+sIL-6R showed formation of a prominent DNA-protein complex with a consensus oligonucleotide for SP4 binding (Fig. 3A) .
No binding was however seen with a consensus motif for SP1. Nuclear extracts from cells stimulated singly with IL-6 and sIL-6R failed to produce any effect.
To verify the specificity of SP4 binding, EMSA was performed with a 100-fold molar excess of an unlabeled SP4 consensus oligonucleotide ( Fig. 3B ). This competition assay inhibited detection of the SP4-DNA complex. In turn, EMSA with a specific anti-SP4 antibody led to a supershift of the DNA-protein complex ( Fig. 3B ). Furthermore, transfection of a mutant construct specific to the SP4 binding site completely eliminated VEGF promoter activation after IL-6+sIL-6R stimulation ( Fig. 3C ).
Effect of STAT3 blockade on VEGF production
As SP4 has not been typically associated with IL-6 signal transduction, we examined the activation of STAT3, a key regulator of IL-6 signaling. 23 Indeed, stimulation of HPMC with IL-6+sIL-6R resulted in a time-dependent induction of STAT3, but also of SP4 mRNA ( Fig. 4A and   4B ). To determine if there exists a link between STAT3, SP4 and VEGF, the expression of STAT3 gene was blocked by RNA interference. These experiments showed that STAT3targeting siRNA, but not a scrambled siRNA control, inhibited STAT3 itself at a protein and mRNA level ( Fig. 4C and 4D ). It also inhibited SP4 and VEGF induction by IL-6+sIL-6R ( Fig. 4E and 4F).
Effect of SP4 blockade on VEGF production and angiogenesis
To further confirm the involvement of SP4 in VEGF production and biological activity, HPMC were stimulated with IL-6+sIL-6R in the presence of either SP4-targeting siRNA or scrambled siRNA. The SP4 blockade resulted in a significant inhibition of VEGF protein release ( Fig. 5A ). To test the functional properties of the VEGF production, conditioned medium from stimulated HPMC was transferred to endothelial cell cultures and the formation of capillaries assessed. Incubation of human umbilical vein endothelial cells (of the EA.hy926 line) in the presence of conditioned medium from IL-6+sIL-6R-stimulated HPMC significantly increased endothelial cell tube formation. Similar degree of stimulation was observed when conditioned medium from HPMC treated with scrambled siRNA was used.
However, endothelial cell angiogenesis was significantly less in response to conditioned medium from HPMC treated with siRNA against SP4 (Fig. 5B ). This effect was not unique to specific features of EA.hy926 endothelial cells, but was also observed in cultures of human dermal microvascular endothelial cells (Supplemental Fig. 1 ).
Effect of IL-6 signaling on peritoneal Sp4 and Vegf expression in mice
To test whether IL-6 signaling modulates Vegf expression during peritoneal inflammation, wild-type (WT) and IL-6-deficient (IL6 -/-) mice were challenged (i.p.) with a cell-free supernatant prepared from of a clinical isolate of Staphylococcus epidermidis (SES). 21 At designated time points, Sp4 and Vegf expression in the samples of parietal peritoneum was analyzed by qPCR. As illustrated in Fig. 6A , SES-induced inflammation in WT mice was associated with a time-dependent increase in Vegf mRNA expression. In contrast,
Vegf expression was significantly less in IL6 -/mice. To assess whether this effect was related to sIL-6R activity, WT mice were treated with SES together with soluble gp130 (sgp130), which inhibits IL-6 trans-signaling by the IL-6+sIL-6R complex, but does not inhibit classic IL-6 signaling through IL-6R. 24 Addition of sgp130 significantly decreased Vegf expression in WT mice, which resembled the effect seen in IL6 -/mice and indicated that sIL-6R-mediated effects were involved in regulation of VEGF expression in the inflamed peritoneum.
Having identified SP4 as a mediator of IL-6 trans-signaling in human cells, we next examined peritoneal expression of Sp4 in mice. Induction of peritoneal inflammation with SES led to a time-dependent increase in Sp4 expression in WT mice, but not in IL6 -/animals.
In WT mice administered with sgp130, the expression of Sp4 followed the pattern seen in IL6 -/mice ( Fig. 6B ).
Effect of IL-6 signaling in mice on peritoneal expression of genes essential for VEGF activity
To determine whether VEGF induced in the peritoneum by IL-6-signaling can initiate events leading to increased vascular permeability and angiogenesis, we examined expression of several key endothelial-specific targets involved in these processes. 25 These included VEGF receptors (Vegfr2 and Vegfr3), junctional proteinsvascular endothelial cadherin (VE-Cad) and platelet/endothelial cell adhesion molecule 1 (Pecam1), markers of arterial commitment neuropilin 1 (Nrp1) and ephrinB2 (Efnb2), and a marker of lymphatic commitmentpodoplanin (Pdpn). Expression of all these angiogenesis-related targets increased significantly within 24 hours of SES-induced inflammation in WT mice but not in IL6 -/mice and not in WT mice receiving sgp130 ( Fig. 7) .
Effect of IL-6 signaling on peritoneal vasculature during recurrent inflammation in mice
To test whether these acute consequences of increased IL-6 signaling are associated with changes in peritoneal vasculature in the long term, we analyzed the parietal peritoneum of WT and IL6 -/mice challenged repeatedly with SES, as described previously. 26 After four sequential rounds of acute inflammation, the parietal peritoneum of WT animals appeared only modestly vascularized, but consistently showed increased numbers of vessels staining positively for PECAM-1 (CD31) and podoplanin (gp38) in comparison with IL6 -/mice (Supplemental Fig.2 ).
Effect of STAT3/SP4-mediated IL-6 signaling on dialysate-induced VEGF expression in peritonitis
As peritoneal effluents may contain high levels of IL-6 and sIL-6R during peritonitis, we have asked whether such effluents could induce VEGF in HPMC through a signaling pathway identified. Confirming earlier reports, 21;27 we have detected significantly elevated concentrations of IL-6 and sIL-6R in the dialysate drained from PD patients during an acute phase of peritonitis ( Fig. 8A ). When an exemplary PD effluent from a patient with peritonitis was added to the culture medium, it stimulated VEGF, STAT3 and SP4 mRNA expression in a concentration-dependent manner (Fig. 8B ). The increase in VEGF mRNA was reduced to Deleted: see Deleted: can be control levels in the presence of either STAT3 siRNA or SP4 siRNA, but not of the scrambled siRNA ( Fig. 8C) . Interestingly, the inhibition of STAT3 signaling resulted also in a decreased expression of SP4 and STAT3 itself. In contrast, the SP4blockade reduced the expression of SP4, but not of STAT3.
DISCUSSION
The diversity of IL-6 functions is now well appreciated. 28 These pleiotropic activities are partly related to the complexity of IL-6 signaling, which allows even cells without the cognate IL-6R to respond to IL-6. Here, we demonstrate through a series of in vitro and in vivo experiments and the analysis of clinical samples from PD patients that a mechanism of IL-6 trans-signaling can contribute significantly to peritoneal VEGF production. In this respect, we have found that the complex of IL-6 and sIL-6R but not IL-6 alone is capable of inducing de novo VEGF synthesis in HPMC. In the clinical setting, this is most likely to occur during peritonitis since sIL-6R can be then delivered by shedding from infiltrating neutrophils. 21;29 Indeed, we have observed that peritoneal inflammation induced in mice by S. epidermidis, 21 a major causative microorganism of PD-associated peritonitis, resulted in an up-regulation of peritoneal Vegf expression. In contrast, the animals deficient in IL-6 failed to produce such a response. A similar lack of effect could be observed in wild-type mice treated with sgp130. These findings indicated that the induction of Vegf was controlled through sIL-6R rather than by the membrane-bound IL-6R. This mechanism has previously been demonstrated to be instrumental in coordinating leukocyte trafficking during peritonitis. 21 Since STAT3 is the major signal transducer downstream of gp130 23;30 and its involvement in VEGF gene regulation has already been postulated, [31] [32] [33] we have examined the consequences of STAT3 inhibition in HPMC. Indeed, the blockade of STAT3 resulted in an inability of the IL-6+sIL-6R complex to induce VEGF. Surprisingly, however, the progressive '-deletion analysis mapped the IL-6+sIL-6R response element of the VEGF promoter in HPMC to a region that did not contain STAT3 binding elements. Instead, it did contain high affinity binding sites for SP4. Subsequent experiments using EMSA and site-directed mutagenesis confirmed that it was SP4 driving VEGF gene expression in response to IL-6 trans-signaling. Moreover, the blockade of STAT3 inhibited SP4 expression, which positioned STAT3 upstream of SP4 in the signaling cascade. Whilst the targeting of other transcription factors by STAT3 is recognized, 34 the induction of SP4 has not been reported before. The existence of such a signaling axis in vivo was further supported by the observation that S. epidermidis-induced peritoneal inflammation either in IL-6 -/mice or in WT mice administered with sgp130 did not produce an increase in peritoneal Sp4 expression.
The potential of IL-6 to drive VEGF expression has been observed in several cancer cells 31;32;35-37 and implicated in tumor-associated angiogenesis. 38;39 Interestingly, it has been demonstrated that anti-IL-6 antibody siltuximab reduced STAT3 activation and angiogenesis in IL-6-producing intraperitoneal ovarian cancer xenografts and reduced VEGF levels in patients with ovarian cancer. 40 The exact role of SP4 in these processes remains to be established. The experiments using RNA interference suggested that SP4 might contribute to the regulation of basal VEGF expression in some pancreatic cancer cells lines. 41 The involvement of SP4 could also be inferred from the observation that the down-regulation of VEGF expression by cyclooxygenase inhibitors in human colon cancer cells was associated with proteasomal degradation of SP4. 42 Ablation of STAT3 has long been considered an attractive therapeutic strategy for IL-6-mediated inflammation and cancer. 43;44 Our findings suggest that SP4 activity is downstream of STAT3 activation in response to IL-6 trans-signaling. Thus, a therapeutic targeting of SP4 may block specific aspects of IL-6 signaling, whilst leaving STAT3 activity intact. That blocking SP4 can indeed produce viable biological effects could be demonstrated by experiments that showed a decrease in angiogenesis induced by conditioned media from HPMC exposed to the IL-6+sIL-6R complex in the presence of SP4-silencing RNA.
The consequences of VEGF up-regulation by IL-6 trans-signaling in the setting of PD can be twofold. As VEGF is a potent vascular permeabilizing agent, its rise during acute peritonitis will cause extravasation of fluid rich in plasma proteins, which together with migrating leukocytes will form an inflammatory infiltrate essential for the clearance of infection. The process would be self-limiting given the massive, but short-lived increase in intraperitoneal IL-6 levels 21;27 and the role of IL-6 trans-signaling in suppressing neutrophilspecific chemokines 21 and promoting neutrophil apoptosis. 45 Indeed, it has been demonstrated that the IL-6+sIL-6R complex can induce STAT3-and VEGF-mediated vascular leakage through microvascular endothelial cells. 46 On the other hand, repeated episodes of peritonitis and the persistent IL-6+sIL-6Rmediated VEGF stimulation may lead to formation of new hyperpermeable blood vessels, as found in many chronic inflammatory diseases. 47 The accumulation of fibrin in tissues favors fibroblast migration and subsequent extracellular matrix synthesis. In this respect, it has recently been demonstrated that recurrent peritoneal inflammation in mice leads to tissue fibrosis through a process that is strictly dependent on IL-6, albeit in this particular model related to STAT1 and IFN- signaling. 26 Moreover, it has been demonstrated that experimental peritoneal fibrosis in mice could be reduced by antagonizing VEGF through soluble VEGF type I receptor. 48 We observed that SES-induced inflammation in WT mice was associated with increased expression of key mediators of VEGF signaling, new vessel formation 25 and vascular remodeling. 49 In this respect, increased expression of Pecam1 and VE-Cad likely reflect endothelial cell expansion in vivo but might also be a secondary response, either to transient rearrangement of intercellular junctions that underlie increased permeability or to degradation of junctional proteins by inflammation-induced proteases. 50 Importantly, these increases in endothelial markers were mediated directly by IL-6 transsignaling as they did not occur in IL-6 -/mice and could be reduced in WT mice by specific blockade with sgp130.
Moreover, these early events in IL-6 signaling during acute inflammation may also contribute to chronic changes in the peritoneal vasculature. We have observed increased immunostaining for PECAM-1 and podoplanin in WT mice subjected to repeated episodes of peritonitis compared with IL-6 -/mice. Of particular interest is the increased number of podoplanin-positive cells in this setting, as increased expression of podoplanin was consistently detected in PD patients with encapsulating peritoneal sclerosis (EPS). 51;52 Furthermore, recent data from the GLOBAL study showed that patients who developed EPS had earlier had higher dialysate levels of IL-6 during PD. 53 These two scenarios would fit well into the concept that depending on a pathophysiological context, IL-6 can either be crucial for host defense or promote chronic disease. 28 Here, we demonstrate that dialysate IL-6 and sIL-6R can act together through the trans-signaling pathway controlled by the STAT3-SP4 axis to up-regulate mesothelial VEGF production during peritonitis. The identification of this novel mechanism that controls peritoneal VEGF expression at the transcriptional level may help to understand better how peritoneal inflammation and angiogenesis contribute to adverse peritoneal membrane remodeling during peritoneal dialysis.
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CONCISE METHODS
Materials
Unless stated otherwise, all chemicals were from Sigma-Aldrich (St Louis, MO, USA) and all culture plastics were Falcon  from Becton Dickinson (Franklin Lakes, NJ, USA). Cell culture media and buffers were from Biochrom AG (Berlin, Germany) and fetal calf serum was from Invitrogen (Darmstadt, Germany). Human recombinant IL-6 and sIL-6R were from R&D Systems (Wiesbaden, Germany). Antibodies against STAT3 and SP4 were from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany).
Mesothelial cell culture
HPMC were isolated from the specimens of omentum obtained from consenting patients undergoing elective abdominal surgery. Cells were cultured and characterized as described in detail elsewhere. 20 For the experiments, cells were rendered quiescent by serum deprivation for 48 hours and then stimulated with IL-6 and/or sIL-6R as specified in the legends to figures. All experiments were performed with cells no older than from the third passage to minimize the number of senescent cells, as this may affect the level of VEGF released. 54 
Endothelial cell culture and tube formation assay
Immunoassays
Concentrations of VEGF, IL-6 and sIL-6R were measured using DuoSet ® Immunoassay Kits R&D S ste s . All assa s ere desig ed a d perfor ed as per a ufacturer's i structio s.
Gene expression analysis
The expression of target genes was assessed with reverse transcription and quantitative PCR (RT-qPCR), essentially as described previously. 20 PCR conditions and primer sequences were as specified in Supplemental Data.
DNA Constructs and Reporter Plasmids
Progressi e VEGF '-deletion luciferase plasmids (pLuc 2068, pLuc 1340, pLuc 840, pLuc 318, and pLuc 102) were kindly provided by Dr. A. Scholz (Charité-Universitätsmedizin, Berlin, Germany). The constructs were generated as reported previously, 57 and checked for the correct length by restriction digest. To target the SP4 binding site at position -73 to 75 (TGA) within the VEGF promoter, the desired sequence (AAA) was inserted into the pLuc VEGF 318 construct using the Q5 site-directed mutagenesis kit (New England BioLabs, Franfurt, Germany) with forward primer 5′-GGGGCGGGCCaaaGGCGGGGTCCC -3′ and reverse primer 5′-GGGGGGCGGGGACAGGCG -3′.
Transfection studies
Transient transfection and luciferase assays were performed as previously described in detail. 20 Transfections with siRNAs were performed with the siRNA Transfection Reagent and siRNAs for STAT3 (sc-44275), SP4 (sc-36545), or with scrambled siRNA control (sc-37007) as per a ufacturer's i structio s all aterials fro Sa ta Cruz Biotech olog , Heidelberg, Germany).
Computational analysis of the VEGF promoter
The human VEGF promoter region -268 to -51 (GenBank NT_007592.15) was analyzed by PROMO virtual laboratory (http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) for the presence and location of potential transcription factor binding sites.
Nuclear extracts and electrophoretic mobility shift assay
Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit 
Western blotting
Cell extracts were prepared as described, 58 
Peritoneal dialysis effluent
Peritoneal effluent was obtained from consenting patients undergoing continuous ambulatory PD. Dialysate was collected either from stable PD patients after a routine 4-hr dwell or from the first bag drained from patients presenting with an episode of peritonitis.
Samples were processed as described previously. 59
Animal experiments
All animal procedures were performed under appropriate licenses and according to institutional animal care guidelines. The experiments were performed in weight-matched 7to 12-wk-old inbred C57BL/6J wild-type (WT) and IL-6-deficient (IL6 -/-) mice, as previously described. 45 Peritoneal inflammation was established through i.p. administration of 500 µl of a cell-free supernatant (SES) prepared from S. epidermidis isolated from a PD patient, as detailed elsewhere. 60 Repeated challenge with SES was used to model recurrent peritoneal inflammation, essentially as described previously. 26 Animals were sacrificed at designated time points and specimens of peritoneal peritoneum were collected and snap frozen in liquid nitrogen. The tissue samples were then homogenized in Tri Reagent (Invitrogen) and total RNA was prepared according to the manufacturer's i structio s. Additional biopsy samples were processed for immunohistochemistry, as described 26 EMSA oligo sequences for SP1 and SP4 GCGGGCCGGGGGCGGGGTCCCGGC SP4 -59 to -82 TCGCCTGTCCCCGCCCCCCGGGGC SP1 -80 to -103
Site directed mutagenesis of SP4 sequences GGGGCGGGCCaaaGGCGGGGTCCC site directed mutagenesis forward Primer
Nucleotides written in CAPITAL LETTERS correspond to VEGF promoter sequence -267 to 0. Nucleotides written in small letters correspond to VEGF gene sequence +1 to+50.
A sequence in dark green was used as a synthethic oligo for SP1 EMSA experiments A sequence in light green was used as a synthethic oligo for SP4 EMSA experiments. Mutated SP4 sequence is written in small blue letters. 
